Preview

Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения гиперпролактинемии

https://doi.org/10.14341/probl201359619-26

Полный текст:

Аннотация

Доказательной базой для рекомендаций являются публикации, вошедшие в Кокрановскую библиотеку, базы данных EMBASE и MEDLINE.

Об авторах

Г А Мельниченко
Институт клинической эндокринологии ФГБУ "Эндокринологический научный центр", Минздрава РФ, Москва
Россия


Л К Дзеранова
Институт клинической эндокринологии ФГБУ "Эндокринологический научный центр", Минздрава РФ, Москва
Россия


Е А Пигарова
Институт клинической эндокринологии ФГБУ "Эндокринологический научный центр", Минздрава РФ, Москва
Россия


С Ю Воротникова
Институт клинической эндокринологии ФГБУ "Эндокринологический научный центр", Минздрава РФ, Москва
Россия


Л Я Рожинская
Институт клинической эндокринологии ФГБУ "Эндокринологический научный центр", Минздрава РФ, Москва
Россия


И И Дедов
Институт клинической эндокринологии ФГБУ "Эндокринологический научный центр", Минздрава РФ, Москва
Россия


Список литературы

1. Дедов И.И., Мельниченко Г.А., Романцова Т.И. Синдром гиперпролактинемии. М: Триада 2004.

2. Дедов И.И., Мельниченко Г.А., Романцова Т.И., Рожинская Л.Я., Дзеранова Л.К., Иловайская И.А., Далантаева Н.С., Бармина И.И. Гиперпролактинемия. Современные подходы и старые проблемы. Вестн репрод здоровья 2009; 2: 2-8.

3. Дзеранова Л.К., Табеева К.И., Гончаров Н.П., Колесникова Г.С, Добрачева А.Д. Макропролактинемия. Пробл репрод 2005; 11: 2: 60-65.

4. Мельниченко Г.А., Марова Е.И., Дзеранова Л.К., Вакс В.В. Гиперпролактинемия у женщин и мужчин: Пособие для врачей. М 2008.

5. Иловайская И.А. Диагностика и лечение гиперпролактинемии: клинические рекомендации Международного эндокринологического общества и взгляд российских экспертов. Акуш и гинекол 2012; 1: 2-7.

6. Клиническая нейроэндокринология. Под ред. И.И. Дедова. М 2011; 113-118.

7. Ларина А.А., Григорян О.Р., Андреева Е.Н., Дзеранова Л.К. Гиперпролактинемия и беременность. Пробл репрод 2013; 3: 13-17.

8. Klibanski A. Prolactinomas. N Engl J Med 2010; 362: 1219-1226.

9. Melmed S., Casanueva F.F., Hoffman A.R., Kleinberg D.L., Montori V.M., Schlechte J.A. et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metabol 2011; 96: 273-288.

10. Casanueva F., Molitch M., Schlechte J., Abs R., Bonert V., Bronstein M.D. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxford) 2006; 65: 265-273.

11. Petakov M.S., Damjanovia S.S., Nikolia-Durovia M.M., Dragojlovia Z.L., Obradovia S., Gligorovia M.S. et al. Pituitary adenomas secreting large amounts of prolactin may give false low values ininmunoradiometric assays. The hook effect. J Endocrinol Invest 1998; 21: 184-188.

12. McKenna T.J. Should macroprolactin be measured in all hyperprolactinaemic sera? Clin Endocrinol (Oxford) 2009; 71: 466-469.

13. Gibney J., Smith T.P., Mac Kenn T.J. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metabol 2005; 90: 3927-3932.

14. Molitch M.E. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005; 80: 1050.

15. Famini P., Maya M.M., Melmed S. Pituitary magnetic resonance imaging for sellar and parasellar masses: ten-year experience in 2598 patients. J Clin Endocrinol Metabol 2011; 96: 1633-1641.

16. Ikeda H., Abe T., Watanaba K. Usefulness of composite methionine-positron emission tomography/3.0-tesla magnetic resonance imaging to detect the localization and extent of early-stage Cushing adenoma. J Neurosurg 2010; 112: 750-755.

17. Elston M.S., McDonald K.L., Clifton-Bligh R.J., Robinson B.G. Familial pituitary tumor syndromes. Nat Rev Endocrinol 2009; 5: 453-461.

18. Gillam M.P., Molitch M.E., Lombardi G., Colao A. Advances in the treatment of prolactinomas. Endocrinol Rev 2006; 27: 485-534.

19. Schlechte J., Dolan K., Sherman B., Clapler F., Luciano A. The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metabol 1989; 68: 412-418.

20. Webster J., Piscitelli G., Polli A., Ferrari C.I., Ismail I., Scanlon M.F. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N Engl J Med 1994; 331: 904-909.

21. Leong K.S., Foy P.M., Swift A.C., Atkin S.L., Hadden D.R., Mac Farlane I.A. CSF rhinorrhoea following treatment with dopamine agonists for massive invasive prolactinomas. Clin Endocrinol (Oxford) 2000; 52: 43-49.

22. Iyer P., Molitch M.E. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas. Endocrinol Pract 2011; 17: 55-58.

23. Ono M., Miki N., Kawamata T., Makino R., Amano K., Seki T. et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J Clin Endocrinol Metabol 2008; 93: 4721-4727.

24. Delgrange E., Daems T., Verhelst J., Abs R., Maiter D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 2009; 160: 747-752.

25. Herring N., Szmigielski C., Becher H., Karavitaki N., Wass J.A. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin Endocrinol (Oxford) 2009; 70: 104-108.

26. Vallette S., Serri K., Rivera J., Santagata P., Delorme S., Garfield N. et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 2009; 12: 153-157.

27. Wakil A., Rigby A.S., Clark A.L., Kallvikbacka-Bennett A., Atkin S.L. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur J Endocrinol 2008; 159: 11-14.

28. Valassi E., Klibanski A., Biller B.M.K. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metabol 2010; 95: 1025-1033.

29. Klibanski A. Dopamine agonist therapy in prolactinomas: when can treatment be discontinued. J Clin Endocrinol Metabol 2009; 94: 2247-2249.

30. Barber T.M., Kenkre J., Garnett C., Scott R.V., Byrne J.V., Wass J.A.H. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy with prolactinoma occurs commonly specially in macroprolactinoma. Clin Endocrinol (Oxford) 2011; 75: 819-824.

31. Ciccarelli E., Grottoli S., Razzore P., Gaia D., Bertagna A., Cirillo S. et al. Long-term treatment with cabergoline, a new long-lasting ergoline derivate, in idiopathic or tumourous hyperprolactinaemia and outcome of drug-induced pregnancy. J Endocrinol Invest 1997; 20: 547-551.

32. Barker II F.G., Klibanski A., Swearingen B. Transsphenoidal surgery for pituitary tumors in the United States, 1996-2000: mortality, morbidity, and the effects of hospital and surgeon volume. J Clin Endocrinol Metabol 2003; 88: 4709-4719.

33. Soule S.G., Farhi J., Conway G.S., Jacobs H.S., Powell M. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy. Clin Endocrinol (Oxford) 1996; 44: 711-716.

34. Babey M., Sahli R., Vajtai I., Andres R.H., Seiler R.W. Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonist. Pituitary 2011; 14: 222-230.

35. Amar A.P., Couldwell W.T., Chen J.C., Weiss M.H. Predictive value of serum prolactin levels measured immediately after transsphenoidal surgery. J Neurosurg 2002; 97: 307-314.

36. Massoud F., Serri O., Hardy J., Somma M., Beauregard H. Transsphenoidal adenomectomy for microprolactinomas: 10-20 years of follow-up. Surg Neurol 1996; 45: 341-346.

37. Tanaka S., Link M.J., Brown P.D., Stafford S.L., Young W.F., Pollock B.E. Gamma knife radiosurgery for patients with prolactin-secreting pituitary adenomas. World Neurosurg 2010; 74: 147-152.

38. Brada M., Ajiyhkumar T.V., Minniti C. Radiosurgery for pituitary adenomas. Clin Endocrinol (Oxford) 2004; 61: 531-534.

39. Molitch M. Prolactinomas and pregnancy. Clin Endocrinol (Oxford) 2010; 73: 147-148.

40. Gonzalez J.G., Elizondo G., Saldivar D., Nanez H., Todd L.E., Villarreal J.Z. Pituitary gland growth during normal pregnancy: in vivo study using magnetic resonance imaging. Am J Med 1988; 85: 217-220.

41. Colao A., Abs R., Barcena D.G., Chanson P., Paulus W., Kleinberg D.L. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study. Clin Endocrinol (Oxford) 2008; 68: 66-71.

42. Stalldecker G., Mallea-Gil M.S., Guitelman M., Alfieri A., Ballarino M.C., Boero L. et al. Effects of cabergoline on pregnancy and embryo-fetal development: retrospective study on 103pregnancies and a review of the literature. Pituitary 2010; 1: 345-350.

43. Colao A., Loche S. Prolactinomas in children and adolescents. Endocrinol Dev Basel Karger 2010; 17: 146-159.

44. Karunakaran S., Page R.C., Wass J.A. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin Endocrinol (Oxford) 2001; 54: 295-300.

45. Thapar K., Kovacs K., Scheithauer B.W., Stefaneanu L., Horvath E., Pernicone P.J. et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1antibody. Neurosurgery 2004; 61: 111-116.

46. Lim S., Shahinian H., Maya M.M., Yong W., Heaney A.P. Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 2006; 7: 518-520.

47. Cormack A.I., McDonald K.L., Gill A.J., Clark S.J., Burt M.G., Campbell K.A. et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin Endocrinol (Oxford) 2009; 71: 226-233.

48. Luque G.M., Pérez-Millán M.I., Ornstein A.M., Cristina C., Becu-Villalobos D. Inhibitory effects of antivascular endothelial growth factor strategies in experimental dopamine-resistant prolactinomas. J Pharmacol Exp Ther 2011; 337: 766-774.

49. Lau Q., Scheithauer B., Kovacs K., Horvath E., Syro L.V., Lloyd R. MGMT immunoexpression in aggressive pituitary adenoma and carcinoma. Pituitary 2010; 13: 367-379.


Для цитирования:


Мельниченко Г.А., Дзеранова Л.К., Пигарова Е.А., Воротникова С.Ю., Рожинская Л.Я., Дедов И.И. Федеральные клинические рекомендации по клинике, диагностике, дифференциальной диагностике и методам лечения гиперпролактинемии. Проблемы Эндокринологии. 2013;59(6):19-26. https://doi.org/10.14341/probl201359619-26

For citation:


Mel'nichenko G.A., Dzeranova L.K., Pigarova E.A., Vorotnikova S.I., Rozhinskaia L.I., Dedov I.I. RUSSIAN ASSOCIATION OF ENDOCRINOLOGISTS NATIONAL PRACTICE GUIDELINES (CLINICAL SIGNS, DIAGNOSIS, DIFFERENTIAL DIAGNOSIS, TREATMENT). Hyperprolactinemia. Problems of Endocrinology. 2013;59(6):19-26. (In Russ.) https://doi.org/10.14341/probl201359619-26

Просмотров: 42


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 0375-9660 (Print)
ISSN 2308-1430 (Online)